Tradestie Institutional Equity Comparison Engine
IBO vs CLYM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IBO Overall Edge
IBO Captures Institutional Edge (3โ0 Pillars ยท 5โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Impact BioMedical, Inc. (IBO) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, IBO trades at N/M Forward P/E with -12621.0% operating margin (+16.7% YoY revenue) versus CLYM at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, IBO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
IBO
IBO N/M vs CLYM N/M Fwd P/E
Growth & Margin Winner
IBO
Op Margin -12621.0% vs 0.0% ยท YoY +16.7% vs +0.0%
Momentum & Technical Winner
IBO
1Y +862.8% vs +431.6% ยท 52W Pos 67% vs 50%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
IBO
NYSE American
Impact BioMedical, Inc.
Pharmaceutical Preparations
$4.91
-4.47% 1D
Market Cap
$44.4M
1M Return
+83.21%
1Y Return
+862.75%
Forward P/E
N/M
Unified AI Score
36.8 / 100
SELL
Tech 15.0
Fund 32.0
Flow 50.0
Mom 40.0
CLYM
NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.94
-4.05% 1D
Market Cap
$608.5M
1M Return
+1.22%
1Y Return
+431.55%
Forward P/E
N/M
Unified AI Score
41.9 / 100
SELL
Tech 38.0
Fund 42.0
Flow 50.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
IBO +862.75%
CLYM +431.55%
Spread: +431.2 pp (IBO Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
IBO TTM Op. Margin: -12621.0%
CLYM TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IBO vs CLYM. Trailing 12-month operating profitability (IBO -12621.0% vs CLYM 0.0%) and valuation multiples (IBO N/M vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IBO | CLYM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $44.4M | $608.5M | Larger Scale | CLYM |
| Trailing P/E Ratio Valuation | 0.4x | N/M | Lower Multiple | IBO |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +16.7% | +0.0% | Higher Growth | IBO |
| Operating Margin (TTM) Profitability | -12621.0% | 0.0% | Higher Margin | CLYM |
| Net Profit Margin Profitability | 4247.4% | 0.0% | Higher Margin | IBO |
| Return on Equity (ROE) Capital Efficiency | 71.2% | -29.3% | Higher ROE | IBO |
| 52-Week Range Position Momentum | 67% ($0โ$7) | 50% ($2โ$18) | Stronger Trend | IBO |
| Beta / 30D Volatility Risk Regime | -6.72ฮฒ ยท 120% Vol | 1.50ฮฒ ยท 114% Vol | Lower Realized Risk | CLYM |
| Unified Institutional Score Composite Signal | 36.8 / 100 (SELL) | 41.9 / 100 (SELL) | Higher Composite | CLYM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full IBO vs CLYM Buy Guide
IBO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CLYM
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither IBO nor CLYM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.